Amgen Stock Adds Good Weight After CEO's Update On Experimental Drug Rivaling Ozempic, Nixing Oral Weight-Loss Candidate
Amgen, Inc. AMGN shares rallied over 14% in Thursday’s after-hours trading after the biopharma reported a double beat and offered an update on its obesity drug pipeline. What Happened: Amgen said on the call that it was pulling the plug on AMG 786, an oral …